✨ Your Portfolio is fetched and updated from zerodha.
Micro Pharmaceuticals
Market Cap
₹142 Cr.
P/E
37.37
  • Astonea Labs
  • Beta Drugs
FAQs on Astonea Labs Ltd. Shareprice

There is not enough historical data for the companies share price.

There is insufficient historical data to gauge this.
Latest PE of Astonea Labs is 37.37

Growth Table
  • Astonea Labs Ltd.
  • Beta Drugs
Balance Sheet
  • Astonea Labs Ltd.
  • Beta Drugs
Balance Sheet Snapshot
No data available.
Fund Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end
Profit & Loss
  • Astonea Labs Ltd.
  • Beta Drugs
Cash Flow
  • Astonea Labs Ltd.
  • Beta Drugs
Cash Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
Ratios
= Dominant Factor
  • Astonea Labs Ltd.
  • Beta Drugs
Reverse DCF
locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
FAQs on Astonea Labs Ltd. Financials

Balance sheet of Astonea Labs is moderately strong, But short term working capital might become an issue for this company.

Yes, The net debt of Astonea Labs is increasing.
Latest net debt of Astonea Labs is ₹41.69 Crs as of Mar-24.
This is greater than Mar-23 when it was ₹35.93 Crs.

Yes, profit is increasing.
The profit of Astonea Labs is ₹3.81 Crs for Mar 2024, ₹0.67 Crs for Mar 2023 and ₹0.25 Crs for Mar 2022

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Astonea Labs latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

Companies resources are allocated to majorly unproductive assets like Inventory, Accounts Receivable

Ideas Dashboard
Timeline
Watchlist
Portfolio
Alerts
Research
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech